### **ANNEXURE I**

1. Name of Listed Entity - Glenmark Pharmaceuticals Limited

2. Quarter ending - 31-March-2019

. Co	emposition of Board of Dire	ectors							
Title (Mr./ Ms)	Name of the Director	DIN	Category (Chairperson/ Executive/ Non- Executive/ Independent/ Nominee)	Date of Appointment	Date of cessation	Tenure (Years)	No of Directorship in listed entities including this listed entity	No of memberships in Audit/ Stakeholder Committee(s) including this listed entity	No of post of Chairperson in Audit/ Stakeholder Committee held in listed entities including this listed entity
Mrs.	Blanche E Saldanha	00007641	NED	25-Jul-2014			1	0	0
Mr.	Glenn Saldanha	00050607	C & ED	16-May-2012			1	0	0
Mrs.	Cherylann Pinto	00111844	ED	16-May-2012			1	1	0
Mr.	Julio Francis Ribeiro	00047630	ID	01-Apr-2014		5	1	2	2
Mr.	Rajesh V Desai	00050838	NED	01-April-2017			1	0	0
Mr.	V.S. MANI	01082878	ED	29-05-2018		-	1	0	0
Mr.	Sridhar Gorthi	00035824	ID	01-Apr-2014		5	2	2	1
Mr.	Devendra Raj Mehta	01067895	ID	01-Apr-2014		5	4	3	1
Mr.	Dr. Brian W Tempest	00101235	ID	01-Apr-2014		5	1	0	0
Mr.	Bernard H Munos	05198283	ID	01-Apr-2014		5	1	0	0
Mr.	Milind Sarwate	00109854	ID	29-Oct-2015		5	4 ,	9	2



## II. Composition of Committees

Audit Committee				
Sr. No.	Name of the Director	Category	Chairperson/Membership	
1	Julio Francis Ribeiro	ID	Chairperson	
2	Sridhar Gorthi	ID	Member	
3	Milind Sarwate	. ID	Member	

Stakeho	Stakeholders Relationship Committee				
Sr. No.	Name of the Director	Category	Chairperson/Membership		
1	Julio Francis Ribeiro	ID	Chairperson		
2	Cherylann Pinto	ED	Member		
3	Devendra Raj Mehta	ID	Member		
4	Milind Sarwate	ID	Member		

Risk Ma	Risk Management Committee				
Sr. No.	Name of the Director	Category	Chairperson/Membership		
1	Glenn Saldanha	C & ED	Chairperson		
2	Rajesh V Desai	NED	Member		
3	Devendra Raj Mehta	ID .	Member		
4	V.S. Mani	ED	Member		

	Nomination and Remuneration Committee				
Sr. No.	Name of the Director	Category	Chairperson/Membership		
1	Glenn Saldanha	C & ED	Member		
2	Julio Francis Ribeiro	ID	Chairperson		
3	Sridhar Gorthi	ID	Member		
4	Devendra Raj Mehta	ID	Member		
5	Milind Sarwate	ID	Member		



III. Meet	ing of Board of Direc	ctors	***************************************
Date(s) of the previou	Meeting (if any) in us quarter	Date(s) of Meeting (if any) in the relevant quarter	Maximum gap between any two consecutive (in number of days)
13-Nov-20	18	14-Feb-2019	92
13-Nov-20	18	14-Feb-2019	

V. Meeting of Committe	ees			
Name of the committee	Date(s) of meeting of the committee in the relevant quarter	Whether requirement of Quorum met (details)	meeting of the	Maximum gap between any two consecutive (in number of days)
Audit Committee	13-Feb-2019	Yes	12-Nov-2018	
Nomination and Remuneration Committee	14-Feb-2019	Yes	13-Nov-2018	92
Stakeholders Relationship Committee	14-Feb-2019	Yes	13-Nov-2018	

V. Related Party Transactions	
Subject	Compliance status (Yes/No/NA)
Whether prior approval of audit committee obtained	Yes
Whether shareholder approval obtained for material RPT	Not Applicable
Whether details of RPT entered into pursuant to omnibus approval have been reviewed by Audit Committee	Yes



#### VI. Affirmations

- 1. The composition of Board of Directors is in terms of SEBI (Listing obligations and disclosure requirements) Regulations, 2015. Yes
- 2. The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015
  - a. Audit Committee Yes
  - b. Nomination & remuneration committee Yes
  - c. Stakeholders relationship committee Yes
  - d. Risk management committee (applicable to the top 100 listed entities) Yes
- 3. The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015. Yes
- 4. The meetings of the board of directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.- Yes
- 5. a. This report and/or the report submitted in the previous quarter has been placed before Board of Directors. Yes
  - b. Any comments/observations/advice of Board of Directors may be mentioned here:





## **ANNEXURE II**

# Format to be submitted by listed entity at the end of the financial year (for the whole of financial year)

I. Disclosure on website in terms of Listing Regulations	
ltem	Compliance status
	(Yes/No/NA)
Details of business	Yes
Terms and conditions of appointment of independent directors	Yes
Composition of various committees of board of directors	Yes
Code of conduct of board of directors and senior management personnel	Yes
Details of establishment of vigil mechanism/ Whistle Blower policy	Yes
Criteria of making payments to non-executive directors	Yes
Policy on dealing with related party transactions	Yes
Policy for determining 'material' subsidiaries	Yes
Details of familiarization programmes imparted to independent directors	Yes
Contact information of the designated officials of the listed entity who are responsible for assisting and handling	Yes
Email address for grievance redressal and other relevant details	Yes
Financial results	Yes
Shareholding pattern	Yes
Details of agreements entered into with the media companies and/or their associates	Not Applicable
New name and the old name of the listed entity	Not Applicable

I Annual Affirmations				
Particulars	Regulation Number	Compliance status (Yes/No/NA)		
Independent director(s) have been appointed in terms of specified criteria of	16(1)(b) & 25(6)	Yes		
'independence' and/or 'eligibility'				
Board composition	17(1)	Yes		
Meeting of Board of directors	17(2)	Yes		
Review of Compliance Reports	17(3)	Yes		
Plans for orderly succession for appointments	17(4)	Yes		
Code of Conduct	17(5)	Yes		
Fees/compensation	17(6)	Yes		
Minimum Information	17(7)	Yes		
Compliance Certificate	17(8)	Yes		
Risk Assessment & Management	17(9)	Yes		
Performance Evaluation of Independent Directors	17(10)	Yes		
Composition of Audit Committee	18(1)	Yes		
Meeting of Audit Committee	18(2)	Yes		
Composition of nomination & remuneration committee	19(1) & (2)	Yes		
Composition of Stakeholder Relationship Committee	20(1) & (2)	Yes		
Composition and role of risk management committee	21(1),(2),(3),(4)	Yes		
Vigil Mechanism	22	Yes		
Policy for related party Transaction	23(1),(5),(6),(7) & (8)	Yes		
Prior or Omnibus approval of Audit Committee for all related party transactions	23(2), (3)	Yes		



Approval for material related party transactions	23(4)	Not Applicable
Composition of Board of Directors of unlisted material Subsidiary	24(1)	Not Applicable
Other Corporate Governance requirements with respect to subsidiary of listed entity	24(2),(3),(4),(5) & (6)	Yes
Maximum Directorship & Tenure	25(1) & (2)	Yes
Meeting of independent directors	25(3) & (4)	Yes
Familiarization of independent directors	25(7)	Yes
Memberships in Committees	26(1)	Yes
Affirmation with compliance to code of conduct from members of Board of Directors and Senior management personnel	26(3)	Yes
Disclosure of Shareholding by Non- Executive Directors	26(4)	Yes
Policy with respect to Obligations of directors and senior management	26(2) & 26(5)	Yes

#### **III Affirmations:**

The Listed Entity has approved Material Subsidiary Policy and the Corporate Governance requirements with respect to subsidiary of Listed Entity have been complied. - Yes

Name

Harish Kuber

Designation

**Company Secretary & Compliance Office**